Navigation Links
Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
Date:11/17/2016

NORTHBROOK, Ill., Nov. 17, 2016 /PRNewswire/ -- Astellas today announced two gilteritinib abstracts, including an oral presentation in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML), that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 3-6 in San Diego.

The following abstract will be presented during an oral presentation session:

Continue Reading
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.

Title: Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). (Abstract 1069)

Presenter: Alexander E. Perl, M.D., University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, Pa.

  • Session Date/Time: Monday, Dec. 5 at 4:30 p.m. PST
  • Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)

In addition to the oral presentation, Astellas will present the following abstract in a poster session:

Title: Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia (Yoko Ueno, PhD) (Abstract 2830)

  • Session Date/Time: Sunday, Dec. 4 from 6:00 p.m. to 8:00 p.m. PST
  • Location: Hall GH (San Diego Convention Center)

About Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.

Logo - http://photos.prnewswire.com/prnh/20140416/84970

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-oncology-announces-new-data-in-acute-myeloid-leukemia-to-be-presented-at-the-2016-ash-annual-meeting-300365503.html


'/>"/>
SOURCE Astellas
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen
2. Amgen And Astellas Announce Japan Alliance
3. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
4. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
5. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the AT&T National
6. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
7. Astellas Appoints New Senior Vice President of Global Oncology Development
8. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
9. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
10. Astellas Employees to Change Tomorrow through Annual Day of Service
11. Astellas US Appoints Senior Vice President, Chief Communications Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):